Editas Medicine to Participate in Upcoming Investor Conferences
September 01 2022 - 6:30AM
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing
company, today announced that management will participate in the
following upcoming investor conferences:
- 2022 Wells Fargo Healthcare Conference Format:
Fireside ChatDate: Wednesday, September 7, 2022Time: 1:55 p.m.
ETLocation: Everett, MA
- Morgan Stanley 20th
Annual Global Healthcare Conference Format:
Fireside ChatDate: Monday, September 12, 2022Time: 10:30 a.m.
ETLocation: New York, NY
- Baird 2022 Global Healthcare Conference Date:
Tuesday, September 13, 2022Location: New York, NY
The fireside chats will be webcast live and can be accessed
through the “Investors” section of the Company’s website at
www.editasmedicine.com. An archived replay will be available for
approximately 30 days following each event.
About Editas MedicineAs a leading genome
editing company, Editas Medicine is focused on translating the
power and potential of the CRISPR/Cas9 and CRISPR/Cas12a genome
editing systems into a robust pipeline of treatments for people
living with serious diseases around the world. Editas Medicine aims
to discover, develop, manufacture, and commercialize
transformative, durable, precision genomic medicines for a broad
class of diseases. Editas Medicine is the exclusive licensee of
Harvard and Broad Institute’s Cas9 patent estates and Broad
Institute’s Cas12a patent estate for human medicines. For the
latest information and scientific presentations, please visit
www.editasmedicine.com.
Media Contact:Cristi Barnett(617)
401-0113cristi.barnett@editasmed.com
Investor Contact:Ron Moldaver(617)
401-9052ir@editasmed.com
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart
From Apr 2023 to Apr 2024